Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €2.68 EUR
Change Today +0.026 / 0.98%
Volume 1.9M
SRN On Other Exchanges
Symbol
Exchange
OTC US
BrsaItaliana
Frankfurt
As of 11:30 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

sorin spa (SRN) Snapshot

Open
€2.65
Previous Close
€2.65
Day High
€2.69
Day Low
€2.65
52 Week High
03/6/15 - €3.07
52 Week Low
10/15/14 - €1.63
Market Cap
1.3B
Average Volume 10 Days
2.3M
EPS TTM
€0.11
Shares Outstanding
478.7M
EX-Date
--
P/E TM
24.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for SORIN SPA (SRN)

Related News

No related news articles were found.

sorin spa (SRN) Related Businessweek News

No Related Businessweek News Found

sorin spa (SRN) Details

Sorin S.p.A., together with its subsidiaries, researches, develops, and delivers various therapeutic solutions to treat cardiovascular pathologies. It operates through Cardiac Surgery and Cardiac Rhythm Management (CRM) business units. The company provides disposable biomedical devices and systems, including heart-lung machines, oxygenators, autotransfusion systems and devices, mechanical heart valves, tissue heart valves, structureless valves, and annuloplasty rings for extracorporeal circulation during surgery. It also provides defibrillators and pacemakers, and systems for cardiac resynchronisation treatment, patient management, and cardiac arrhythmia assessment. In addition, the company offers single-use systems for urology, urodynamics, cardiac surgery, and haemodialysis. It serves hospitals, healthcare institutions, distributors, organised purchase groups, and government and private entities in Italy, rest of Europe, North America, and internationally. The company was incorporated in 2004 and is headquartered in Milan, Italy.

3,911 Employees
Last Reported Date: 04/2/15
Founded in 2004

sorin spa (SRN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €713.0K
Chairman, President and Chairman of Executive...
Total Annual Compensation: €629.0K
Compensation as of Fiscal Year 2014.

sorin spa (SRN) Key Developments

Sorin Launches New Generation of Heating and Cooling Systems

Sorin Group has launched the new generation of heating and cooling systems, FlexTherm. A simple, display-guided disinfection procedure, which includes a reminder function, reduces operator time and provides maximum protection against bacteria. The new process takes only 35 minutes operator time once every 14 days. The safe and effective, display-guided procedure eliminates the risk for errors. Streamlining the disinfection process maximizes safety for the patients against infections and reduces the time dedicated to disinfection, helping decrease the overall cost of care for hospitals. FlexTherm is equipped with three water tanks, each with a different temperature setting, allocated to three independent water circuits. This design enables superior temperature control and maximum flexibility for use in various simultaneous applications. Precise water flow measurement ensures efficacy and increased control in energy transfer when heating and cooling the patient.

Sorin Group Announces Launch of Generation of Heating and Cooling Systems FlexTherm

Sorin Group announced the launch of its latest generation of heating and cooling systems, FlexTherm, at FECECT 2015. During open-heart surgery procedures requiring cardiopulmonary bypass, the heating and cooling system is used to control and manage the patient’s body temperature by cooling and re-warming blood during the different phases of surgery, through the oxygenator system, and to cool the cardioplegia solution delivered to achieve the patient’s myocardial protection. A simple, display-guided disinfection procedure, which includes a reminder function, reduces operator time and provides maximum protection against bacteria. The new process takes only 35 minutes operator time once every 14 days. The safe and effective, display-guided procedure eliminates the risk for errors. Streamlining the disinfection process maximizes safety for the patients against infections and reduces the time dedicated to disinfection, helping decrease the overall cost of care for hospitals. FlexTherm is equipped with three water tanks, each with a different temperature setting, allocated to three independent water circuits. This design enables superior temperature control and maximum flexibility for use in various simultaneous applications. Precise water flow measurement ensures efficacy and increased control in energy transfer when heating and cooling the patient. FlexTherm is the latest addition to the Sorin HeartLink System, the first automatically integrated perfusion management system designed for improved patient outcomes, increased clinical efficacy and Goal Directed Perfusion, built on the Sorin S5 perfusion system. It links to the Sorin Connect data management system, which automatically collects, monitors, and records the heating and cooling process during the intervention for complete traceability and data management.

Sorin Group Announces Positive One-Year Safety and Efficacy Data from North American Prospective Trial of Freedom Solo Stentless Pericardial Aortic Valve

Sorin Group announced positive one-year safety and efficacy data from a North American prospective trial of Freedom Solo Stentless Pericardial Aortic Valve. The trial results, which are available online at the European Journal of Cardio-Thoracic Surgerywebsite, were used to obtain FDA approval of Solo Smart in June 2014. In clinical use since 2004, Freedom Solo is a stentless biological prosthesis that provides optimum blood flow and can be implanted faster than other available stentless valves due to a single suture line technique. Solo Smart is based on the same technology platform, but includes a removable stent for straightforward implantation and optimal positioning. 251 patients with aortic valve disease from 15 centers across North America were included in the trial. The mean age was 74.7 ± 7.5 years and concomitant procedures, primarily coronary artery bypass grafting (CABG), were performed in 61.9% of patients at time of implantation. Preoperatively, 54% of patients had NYHA functional class III or IV symptoms. The study demonstrated excellent hemodynamics in terms of Mean Pressure Gradients and Effective Orifice Area at implantation that remained stable up to 1 year. One-year mean gradients for valve sizes 19, 21, 23, 25 and 27 mm were 11.7, 7.8, 6.3, 4.6 and 5.0 mmHg, respectively. At one-year follow-up, 96% of patients (181/189) were in NYHA class I or II functional status, and freedom from structural valve deterioration was 99.5%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRN:IM €2.68 EUR +0.026

SRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $194.55 USD +1.60
Edwards Lifesciences Corp $153.76 USD -2.04
Smith & Nephew PLC 1,135 GBp +11.00
Stentys €5.98 EUR +0.17
Zimmer Biomet Holdings Inc $107.00 USD +0.50
View Industry Companies
 

Industry Analysis

SRN

Industry Average

Valuation SRN Industry Range
Price/Earnings 32.3x
Price/Sales 1.6x
Price/Book 2.0x
Price/Cash Flow 14.7x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORIN SPA, please visit www.sorin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.